Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.108 EUR | -3.05% | -6.90% | -34.55% |
2023 | Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Onxeo SA has Changed its Name to Valerio Therapeutics | CI |
Business Summary
AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
Number of employees: 39
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Oncology Products
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Rest of the World
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 01/21/01 |
Ashish Gulati
CTO | Chief Tech/Sci/R&D Officer | - | - |
Julien Miara
BRD | Director/Board Member | - | 17/20/17 |
Valérie Leroy
IRC | Investor Relations Contact | - | 01/16/01 |
Hui Ping Jiang
LAW | General Counsel | - | - |
Human Resources Officer | - | 10/15/10 | |
Philippe Maitre
PRN | Corporate Officer/Principal | 68 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Mallet
BRD | Director/Board Member | 64 | 14/21/14 |
Khalil Barrage
BRD | Director/Board Member | 59 | - |
Director/Board Member | 60 | 29/11/29 | |
Julien Miara
BRD | Director/Board Member | - | 17/20/17 |
Bryan Giraudo
BRD | Director/Board Member | 48 | 23/21/23 |
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 01/21/01 |
Robert L Coleman
BRD | Director/Board Member | - | 14/21/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,364,273 | 114,123,888 ( 73.93 %) | 287,160 ( 0.1860 %) | 73.93 % |
Company contact information
Valerio Therapeutics SA
49, blvd. du Général Martial Valin
75015, Paris
+33 1 45 58 76 00
http://www.onxeo.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.55% | 18.39M | |
+32.66% | 664B | |
+29.29% | 567B | |
-7.04% | 354B | |
+19.22% | 330B | |
+4.49% | 286B | |
+13.32% | 234B | |
+5.10% | 199B | |
-9.73% | 196B | |
-4.92% | 148B |
- Stock Market
- Equities
- ALVIO Stock
- Company Valerio Therapeutics